<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01204528</url>
  </required_header>
  <id_info>
    <org_study_id>VDRA</org_study_id>
    <nct_id>NCT01204528</nct_id>
  </id_info>
  <brief_title>Vitamin-D Receptor Activation (VDRA) in Chronic Kidney Disease</brief_title>
  <acronym>SOLID</acronym>
  <official_title>Diastolic Dysfunction, Microcirculation Disturbance, Sympathetic Activation and Inflammation in Moderate Kidney Failure and in Diabetic Nephropathy: Disease Modification With Vitamin-D Receptor Activation. A Double-blind, Placebo-controlled, Randomised Trial - the SOLID Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danderyd Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Danderyd Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate whether treatment with a vitamin-D receptor activator is able to improve
      important markers of cardiovascular risk.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Main question:

      May 12 weeks of VDRA treatment reduce the pathological sympathetic overactivation associated
      with moderate kidney disease?

      Secondary questions aim to thrown light on how VDRAs can reduce albuminuria and CRP, i.e.
      does VDRA treatment improve (prespecified statistical analyses):

      A) diastolic dysfunction? B) capillary microcirculation, and whether ameliorated disturbances
      relate to improved diastolic dysfunction? C) endothelial dysfunction and arterial stiffness?
      D) inflammatory activation? E) platelet function and haemostasis? F) levels of antibacterial
      peptides? G) levels of IGFBP-1 and adiponectin?

      Overall design The study is designed as a double-blind, randomised, placebo-controlled trial
      involving two groups (n=72) of patients: 1) chronic kidney failure (CKD, eGFR 15-59 mL/m2)
      and 2) chronic kidney failure and concomitant diabetes mellitus (CKD+DM).

      It will start with a two-week placebo run-in, followed by randomisation to:

        1. Zemplar 1 μg (taken as 1 x 1 μg capsule and one placebo capsule),

        2. Zemplar 2 μg (taken as 2 x 1 μg capsules) and

        3. placebo (taken as two placebo capsules).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A significant reduction in muscle sympathetic nerve activity (MSNA) measured by means of microneurography.</measure>
    <time_frame>Measured after 12 weeks treatment.</time_frame>
    <description>Sympathetic activation is closely related to severity and progression of cardiovascular diseases, and renovascular dysfunction. We will directly measure sympathetic activation using microneurography (muscle sympathetic nerve activity; MSNA), expressed as bursts/minute and bursts/100 RR-interval. As this is a physiological study, the primary outcome will constitute a significant reduction in MSNA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microcirculatory function measured by laser doppler methods.</measure>
    <time_frame>Measured after 12 weeks treatment.</time_frame>
    <description>Assessed by skin laser-doppler methodology, and directly by nailfold capillaroscopy.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Paricalcitol 2 microgram/d</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Paricalcitol 1 microgram/d</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zemplar</intervention_name>
    <description>Vitamin D receptor activator (VDRA)</description>
    <arm_group_label>Paricalcitol 2 microgram/d</arm_group_label>
    <arm_group_label>Paricalcitol 1 microgram/d</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        eGFR 15-59 ml/m2

        Exclusion Criteria:

        Current vitamin D treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Karolinska Institute at Danderyd University Hospital</name>
      <address>
        <city>Danderyd</city>
        <state>Stockholm</state>
        <zip>18288</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2010</study_first_submitted>
  <study_first_submitted_qc>September 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2010</study_first_posted>
  <last_update_submitted>September 4, 2013</last_update_submitted>
  <last_update_submitted_qc>September 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Danderyd Hospital</investigator_affiliation>
    <investigator_full_name>Jonas Spaak</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Dysfunction in CKD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 6, 2016</submitted>
    <returned>June 13, 2016</returned>
    <submitted>June 14, 2017</submitted>
    <returned>January 26, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

